Nemo-Like Kinase (NLK) Is a Pathological Signaling Effector in the Mouse Heart

被引:6
作者
Liu, Ruijie [1 ]
Khalil, Hadi [1 ]
Lin, Suh-Chin J. [1 ]
Sargent, Michelle A. [1 ]
York, Allen J. [1 ]
Molkentin, Jeffery D. [1 ,2 ]
机构
[1] Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45220 USA
[2] Cincinnati Childrens Hosp Med Ctr, Howard Hughes Med Inst, Cincinnati, OH 45229 USA
基金
美国国家卫生研究院;
关键词
GENETIC INHIBITION; INDUCED APOPTOSIS; DROSOPHILA NEMO; CANCER CELLS; IN-VIVO; PATHWAY; HYPERTROPHY; PROTEIN; ACTIVATION; EXPRESSION;
D O I
10.1371/journal.pone.0164897
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Nemo-like kinase (NLK) is an evolutionary conserved serine/threonine protein kinase implicated in development, proliferation and apoptosis regulation. Here we identified NLK as a gene product induced in the hearts of mice subjected to pressure overload or myocardial infarction injury, suggesting a potential regulatory role with pathological stimulation to this organ. To examine the potential functional consequences of increased NLK levels, cardiac-specific transgenic mice with inducible expression of this gene product were generated, as well as cardiac-specific Nlk gene-deleted mice. NLK transgenic mice demonstrated baseline cardiac hypertrophy, dilation, interstitial fibrosis, apoptosis and progression towards heart failure in response to two surgery-induced cardiac disease models. In contrast, cardiac-specific deletion of Nlk from the heart, achieved by crossing a Nlk-loxP allele containing mouse with either a mouse containing a beta-myosin heavy chain promoter driven Cre transgene or a tamoxifen inducible a-myosin heavy chain promoter containing transgene driving a MerCreMer cDNA, protected the mice from cardiac dysfunction following pathological stimuli. Mechanistically, NLK interacted with multiple proteins including the transcription factor Stat1, which was significantly increased in the hearts of NLK transgenic mice. These results indicate that NLK is a pathological effector in the heart.
引用
收藏
页数:14
相关论文
共 36 条
[1]  
Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456
[2]   Drosophila nemo promotes eye specification directed by the retinal determination gene network [J].
Braid, Lorena R. ;
Verheyen, Esther M. .
GENETICS, 2008, 180 (01) :283-299
[3]   Nlk is a murine protein kinase related to Erk/MAP kinases and localized in the nucleus [J].
Brott, BK ;
Pinsky, BA ;
Erikson, RL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (03) :963-968
[4]   Nemo-like kinase promotes etoposide-induced apoptosis of male germ cell-derived GC-1 cells in vitro [J].
Cheng, Xiaowen ;
Liang, Junbo ;
Teng, Yu ;
Fu, Jun ;
Miao, Shiying ;
Zong, Shudong ;
Wang, Linfang .
FEBS LETTERS, 2012, 586 (10) :1497-1503
[5]   Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart -: Cross-talk between cardiac hypertrophic signaling pathways [J].
De Windt, LJ ;
Lim, HW ;
Haq, S ;
Force, T ;
Molkentin, JD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (18) :13571-13579
[6]   A simple protocol for the subcellular fractionation of skeletal muscle cells and tissue [J].
Ivan Dimauro ;
Timothy Pearson ;
Daniela Caporossi ;
Malcolm J Jackson .
BMC Research Notes, 5 (1)
[7]   Nemo-Like Kinase Induces Apoptosis and Inhibits Androgen Receptor Signaling in Prostate Cancer Cells [J].
Emami, Katayoon H. ;
Brown, Lisha G. ;
Pitts, Tiffany E. M. ;
Sun, Xizhang ;
Vessella, Robert L. ;
Corey, Eva .
PROSTATE, 2009, 69 (14) :1481-1492
[8]   Hypertrophy of the heart - A new therapeutic target? [J].
Frey, N ;
Katus, HA ;
Olson, EN ;
Hill, JA .
CIRCULATION, 2004, 109 (13) :1580-1589
[9]   Homodimerization of Nemo-like kinase is essential for activation and nuclear localization [J].
Ishitani, Shizuka ;
Inaba, Kenji ;
Matsumoto, Kunihiro ;
Ishitani, Tohru .
MOLECULAR BIOLOGY OF THE CELL, 2011, 22 (02) :266-277
[10]   The TAK1-NLK-MAPK-related pathway antagonizes signalling between β-catenin and transcription factor TCF [J].
Ishitani, T ;
Ninomiya-Tsuji, J ;
Nagai, S ;
Nishita, M ;
Meneghini, M ;
Barker, N ;
Waterman, M ;
Bowerman, B ;
Clevers, H ;
Shibuya, H ;
Matsumoto, K .
NATURE, 1999, 399 (6738) :798-802